PrintThe Burrill Report
The Burrill Report (April 9, 2012): Forging a Launch Pad for Emerging Growth IPOs (.MP3,11.84 Mb)
On April 5, President Barack Obama signed into law The JOBS Act, legislation intended to provide easier access to public markets for emerging growth companies. The law lowers the cost and regulatory burdens these companies face in raising capital and being public by providing exemptions to existing securities regulations. We spoke to James Lebovitz, corporate and securities partner with the law firm Dechert, about the new law, what it actually does, and what it will mean to capital hungry life sciences companies looking to go public.
April 06, 2012
http://www.burrillreport.com/article-forging_a_launch_pad_for_emerging_growth_ipos.html
REGULATORY
Forging a Launch Pad for Emerging Growth IPOs
Podcast: April 9, 2012[Please login to post comments]
- GAO Sees Gloomy Fiscal Outlook without Health Reform
Long-term simulations show federal deficits and debt on the rise without reforms. Read More - Amgen and AstraZeneca to Collaborate on Inflammation Portfolio
Companies will develop and commercialize five monoclonal antibodies. Read More - Following Late-Stage Failure, Spectrum To Buy Allos
Deals could be worth as much as $206 million. Read More - GE Expands Diagnostic Business with SeqWright Buy
Acquisition adds sequencing capabilities as company seeks to expand services. Read More - Predictive Value of Whole Genome Sequencing Questioned
Study of twins suggests testing would not provide adequate warning of disease risks in most cases. Read More - US Unveils $200 Million Big Data Initiative
Money will be used to advance means of analyzing growing volume of digital data. Read More - BARDA Cuts Funding for Radiation Poisoning Treatment
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More - Covidien Looks to Israel for Novel Medical Devices
Global respiratory specialist acquires two companies in less than a month as medical device deals heat up. Read More - New Report Finds Prescription Drug Spending Flat
Move to generics big reason for drop off. Read More - Celtic Launches ADC Therapeutics with $50 Million
Private equity firm boosts development of antibody-drug conjugates. Read More
.gif)
